In November 2020, Segreto and Deigin wrote that the "genetic structure of SARS-CoV-2 does not rule out a laboratory origin" and found that the "SARS-COV-2 chimeric structure and furin cleavage site might be the result of genetic manipulation."[1]
Qiu.[2]
Magnovvig (talk · contribs · deleted contribs · logs · filter log · block user · block log)
Definitions from Wiktionary
Media from Commons
News from Wikinews
Quotations from Wikiquote
Texts from Wikisource
Textbooks from Wikibooks
Resources from Wikiversity
EU-China CAI edit
The EU-China Comprehensive Agreement on Investment (CAI) is a bilateral treaty between the European Union and the People's Republic of China concerning investment between the parties, but not trade. It has been under negotiation since 2014.[3] The negotiations on the text have concluded on 2020-12-30 following personal involvement of Xi Jinping. [4]
History edit
In May 2021, the von der Leyen Commission suspended efforts to ratify the CAI because "China [had] imposed sanctions on several high-profile members of the European Parliament, three members of national parliaments, two EU committees, and several China-focused European academics" in response to their questions on the Xinjiang genocide and the application of sanctions on four officials from that province. Trade commissioner Valdis Dombrovskis said: "the environment is not conducive to the ratification of the agreement."[5]
References edit
- ^ Segreto, Rossana; Deigin, Yuri (2020). "The genetic structure of SARS‐CoV‐2 does not rule out a laboratory origin". BioEssays. 43 (3): e2000240. doi:10.1002/bies.202000240. PMC 7744920. PMID 33200842.
- ^ . doi:10.1038/scientificamerican0620-24 (inactive 2022-06-26).
{{cite journal}}: Cite journal requires|journal=(help); Missing or empty|title=(help)CS1 maint: DOI inactive as of June 2022 (link) - ^ "EU-China Comprehensive Agreement on Investment". European Commission DG Trade. 27 April 2020. Retrieved 4 June 2020.
- ^ "EU and China reach agreement in principle on investment". European Comission.
- ^ Devonshire-Ellis, Chris (5 May 2021). "The EU Suspends Ratification of CAI Investment Agreement with China: Business and Trade Implications". Dezan Shira & Associates. China Briefing.
GeneOne edit
GeneOne Life Science (GLS) is a KOSPI-listed company headquartered in Seoul, South Korea. The company, whose entry into biotechnology began in 2005, "is focused on gene-based therapies and vaccines". The company changed names twice, from Dong-Il Fabric to VGXI International to its current label in 2014. Its "global clinical development group is based in Blue Bell, Pennsylvania. VGXI Inc. is a wholly owned subsidiary and is based in Woodlands, Texas. VGXI is known as the largest Contract Manufacturing Organization able to supply cGMP-grade DNA plasmids for clinical use.[1]
History edit
Before August 2016, GLS began tests of a DNA vaccine against Zika in Miami, due to the outbreak there which had infected at least 14 people. The injection technique of electroporation is employed by GLS, in which "genes from the virus are shot under high pressure into a person’s arm."[1][2]
In April 2020, GLS and Inovio shared positive results for their MERS DNA vaccine.[3]
In May 2020, GLS announced FDA approval of a Phase 2 Study of their GLS-1200 nasal spray product for COVID-19 prevention. Their product seeks to train cells to produce nitric oxide which "has been shown to inhibit SARS coronavirus growth and infectivity... The study will investigate whether three-times daily nasal administration of GLS-1200 over 4 weeks can prevent infection with COVID-19 while in use."[4]
References edit
- ^ a b Maslow, Joel (2018). "Gene One life science". Human Vaccines & Immunotherapeutics. 14 (11): 1–2. doi:10.1080/21645515.2018.1507374. PMC 6314400. PMID 30346869.
- ^ Regalado, Antonio (2 August 2016). "The U.S. government has begun testing its first Zika vaccine in humans". MIT Technology Review Magazine. Retrieved 2016-08-06.
- ^ "INOVIO and GeneOne Life Science Report Positive Phase 1/2a Clinical Data With DNA Vaccine INO-4700 for MERS Coronavirus at the American Society of Gene & Cell Therapy (ASGCT) Conference". INOVIO Pharmaceuticals. 28 April 2020.
- ^ "GeneOne Life Science Announces US FDA Approval of a Phase 2 Study of GLS-1200 Nasal Spray for COVID-19 Prevention". Vocus PRW Holdings, LLC. PRWeb. 4 May 2020.
Category:Biotechnology Category:Biotechnology companies of the United States Category:Pharmaceutical companies of the United States Category:Research and development in the United States Category:Life sciences industry Category:Pharmaceutical companies of South Korea Category:Biotechnology companies of South Korea Category:Companies listed on KOSPI Category:Applied genetics Category:Bioethics Category:Biotechnology Category:Medical genetics Category:Molecular biology Category:Gene delivery Category:Genetic engineering Category:Zika virus Vaccine Category:Medical research Category:Medical responses to the COVID-19 pandemic Category:Vaccines
Timothy Grayson has been an official at DARPA since at least 2004, when it began the DARPA Grand Challenge for driverless off-road vehicles.[1] Grayson has worked on the DARPA AlphaDogfight.
Grayson spent "several years as a senior intelligence officer with the Central Intelligence Agency (CIA) in the Directorate of Science and Technology", and has worked for the Office of the Director of National Intelligence.[2]
Grayson was invited to speak at the 2019 MILCOM conference,[2] and shared a stage with the IEEE President-elect in a panel discussion at the 2020 IEEE Rising Stars Global conference.[3]
References edit
- ^ "DARPA Challenges Drive Dual-Use Innovation". SPIE. 30 April 2019.
- ^ a b "Timothy "Tim" Grayson, Ph.D. - Profile". AFCEA International. November 2019.
- ^ "Program". IEEE Rising Stars Global 2020.
Category:Living people Category:DARPA Category:American civil servants